Search research articles
Contact Us
Filters
Showing results (241-250 of 283) with videos related to
Page
of 29
Sort By:
Drug and Alcohol Dependence
|
June 9, 2019
Regional differences in white matter integrity in stimulant use disorders: A meta-analysis of diffusion tensor imaging studies
Charlotte L Beard, Joy M Schmitz, Heather E Soder, et al.
Journal of Clinical and Translational Science
|
June 2, 2022
Virtual engagement of under-resourced communities: Lessons learned during the COVID-19 pandemic for creating crisis-resistant research infrastructure
Andrew D Plunk, Alexandra Carver, Charles Minggia, et al.
Psychopharmacology
|
May 3, 2008
Comparison of 50- and 100-g L -tryptophan depletion and loading formulations for altering 5-HT synthesis: pharmacokinetics, side effects, and mood states
Donald M Dougherty, Dawn M Marsh-Richard, Charles W Mathias, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 31, 2018
The 5-HT<sub>2A</sub> Receptor (5-HT<sub>2A</sub>R) Regulates Impulsive Action and Cocaine Cue Reactivity in Male Sprague-Dawley Rats
Dennis J Sholler, Sonja J Stutz, Robert G Fox, et al.
The American Journal of Drug and Alcohol Abuse
|
December 18, 2009
Substance abuser impulsivity decreases with a nine-month stay in a therapeutic community
Susan M Bankston, Deidra D Carroll, Stanley G Cron, et al.
Translational Psychiatry
|
May 6, 2022
A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine
Liangsuo Ma, Kathryn A Cunningham, Noelle C Anastasio, et al.
Neuropharmacology
|
December 25, 2012
Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans
Marco Orrú, Xavier Guitart, Marzena Karcz-Kubicha, et al.
Frontiers in Psychiatry
|
July 19, 2021
Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial
Sade E Johns, Lori Keyser-Marcus, Antonio Abbate, et al.
Drug and Alcohol Dependence Reports
|
January 14, 2025
Phase 1b/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial
Caitlin E Martin, James M Bjork, Lori Keyser-Marcus, et al.
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors
|
September 29, 2022
New approaches to deep phenotyping in addictions
Ashley L Watts, Robert D Latzman, Cassandra L Boness, et al.
Page
of 29
Search research articles
Search
Showing results (241-250 of 283) with videos related to
Sort By:
Page
of 29
Drug and Alcohol Dependence
|
June 9, 2019
Regional differences in white matter integrity in stimulant use disorders: A meta-analysis of diffusion tensor imaging studies
Charlotte L Beard, Joy M Schmitz, Heather E Soder, et al.
Journal of Clinical and Translational Science
|
June 2, 2022
Virtual engagement of under-resourced communities: Lessons learned during the COVID-19 pandemic for creating crisis-resistant research infrastructure
Andrew D Plunk, Alexandra Carver, Charles Minggia, et al.
Psychopharmacology
|
May 3, 2008
Comparison of 50- and 100-g L -tryptophan depletion and loading formulations for altering 5-HT synthesis: pharmacokinetics, side effects, and mood states
Donald M Dougherty, Dawn M Marsh-Richard, Charles W Mathias, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 31, 2018
The 5-HT<sub>2A</sub> Receptor (5-HT<sub>2A</sub>R) Regulates Impulsive Action and Cocaine Cue Reactivity in Male Sprague-Dawley Rats
Dennis J Sholler, Sonja J Stutz, Robert G Fox, et al.
The American Journal of Drug and Alcohol Abuse
|
December 18, 2009
Substance abuser impulsivity decreases with a nine-month stay in a therapeutic community
Susan M Bankston, Deidra D Carroll, Stanley G Cron, et al.
Translational Psychiatry
|
May 6, 2022
A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine
Liangsuo Ma, Kathryn A Cunningham, Noelle C Anastasio, et al.
Neuropharmacology
|
December 25, 2012
Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans
Marco Orrú, Xavier Guitart, Marzena Karcz-Kubicha, et al.
Frontiers in Psychiatry
|
July 19, 2021
Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial
Sade E Johns, Lori Keyser-Marcus, Antonio Abbate, et al.
Drug and Alcohol Dependence Reports
|
January 14, 2025
Phase 1b/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial
Caitlin E Martin, James M Bjork, Lori Keyser-Marcus, et al.
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors
|
September 29, 2022
New approaches to deep phenotyping in addictions
Ashley L Watts, Robert D Latzman, Cassandra L Boness, et al.
Page
of 29